Bronchogen vs Dermorphin
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
BronchogenRecovery & Repair
Dermorphin- Summary
- Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Half-Life
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Admin Route
- SubQ, Oral
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- Research
- —
- —
- Typical Dose
- 10 mg per day
- Not established for human use; research doses vary widely
- Frequency
- Daily for 10–30 days
- Not established
- Key Benefits
- Tissue-specific support for bronchial and lung health
- Promotes normalization of bronchial epithelial cell function
- Potential benefits in chronic bronchitis and COPD support
- Anti-aging effects on pulmonary tissue
- May reduce frequency of respiratory infections
- Supports lung function preservation with aging
- Compatible with other Khavinson bioregulator peptides
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Side Effects
- Generally well tolerated in research studies
- Mild local reactions at injection site (if injected)
- No significant systemic side effects reported at standard doses
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Stacks With
- —
- —